Lexaria Bioscience (LEXX) Competitors $2.29 -0.08 (-3.38%) (As of 01:39 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LEXX vs. ZURA, ELUT, ADAP, FTLF, BMEA, IFRX, NBTX, TELO, ALGS, and PBYIShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Zura Bio (ZURA), Elutia (ELUT), Adaptimmune Therapeutics (ADAP), FitLife Brands (FTLF), Biomea Fusion (BMEA), InflaRx (IFRX), Nanobiotix (NBTX), Telomir Pharmaceuticals (TELO), Aligos Therapeutics (ALGS), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Zura Bio Elutia Adaptimmune Therapeutics FitLife Brands Biomea Fusion InflaRx Nanobiotix Telomir Pharmaceuticals Aligos Therapeutics Puma Biotechnology Lexaria Bioscience (NASDAQ:LEXX) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends. Which has more volatility and risk, LEXX or ZURA? Lexaria Bioscience has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Is LEXX or ZURA more profitable? Zura Bio has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,249.14%. Zura Bio's return on equity of -37.36% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,249.14% -86.10% -80.32% Zura Bio N/A -37.36%-29.81% Do analysts rate LEXX or ZURA? Lexaria Bioscience presently has a consensus price target of $11.00, indicating a potential upside of 380.35%. Zura Bio has a consensus price target of $15.80, indicating a potential upside of 544.90%. Given Zura Bio's higher probable upside, analysts plainly believe Zura Bio is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Zura Bio 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better valuation & earnings, LEXX or ZURA? Lexaria Bioscience has higher revenue and earnings than Zura Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$464.28K86.08-$5.80M-$0.47-4.87Zura BioN/AN/A-$69.24MN/AN/A Does the MarketBeat Community believe in LEXX or ZURA? Zura Bio received 13 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 79.17% of users gave Zura Bio an outperform vote. CompanyUnderperformOutperformLexaria BioscienceOutperform Votes6100.00% Underperform VotesNo VotesZura BioOutperform Votes1979.17% Underperform Votes520.83% Do institutionals and insiders believe in LEXX or ZURA? 13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 26.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to LEXX or ZURA? In the previous week, Zura Bio had 4 more articles in the media than Lexaria Bioscience. MarketBeat recorded 5 mentions for Zura Bio and 1 mentions for Lexaria Bioscience. Zura Bio's average media sentiment score of 0.17 beat Lexaria Bioscience's score of -1.00 indicating that Zura Bio is being referred to more favorably in the news media. Company Overall Sentiment Lexaria Bioscience Negative Zura Bio Neutral SummaryZura Bio beats Lexaria Bioscience on 10 of the 15 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.97M$6.62B$5.20B$9.09BDividend YieldN/A2.98%5.11%4.26%P/E Ratio-4.8710.5987.2817.14Price / Sales86.08204.771,119.08124.12Price / CashN/A57.1543.2337.87Price / Book4.775.174.834.99Net Income-$5.80M$150.75M$120.15M$225.13M7 Day Performance2.69%3.33%2.50%4.01%1 Month Performance9.57%-4.74%17.50%2.89%1 Year Performance78.91%6.36%28.27%17.07% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience2.9219 of 5 stars$2.29-3.4%$11.00+380.3%+91.1%$39.97M$464,278.00-4.877Short Interest ↑ZURAZura Bio3.5342 of 5 stars$2.33+2.2%$15.80+578.1%-46.1%$152.14MN/A0.003Analyst ForecastHigh Trading VolumeELUTElutia3.4585 of 5 stars$4.38-9.5%$10.00+128.3%+93.9%$151.38M$24.78M-1.68180Short Interest ↓ADAPAdaptimmune Therapeutics3.0523 of 5 stars$0.59-2.7%$2.79+373.5%-2.9%$150.64M$175.04M-2.68449Short Interest ↓Positive NewsFTLFFitLife Brands3.0839 of 5 stars$32.25+2.6%$40.00+24.0%+63.8%$148.29M$62.76M19.0820Short Interest ↑BMEABiomea Fusion4.0416 of 5 stars$4.04-4.5%$39.36+874.3%-73.1%$146.41MN/A-1.0150Short Interest ↑IFRXInflaRx2.2552 of 5 stars$2.46+9.8%$8.00+225.2%+54.4%$144.85M$168,498.00-2.2860Short Interest ↑Gap UpNBTXNanobiotix2.0214 of 5 stars$3.00-3.2%$12.00+300.0%-55.3%$141.40M$36.22M0.00100Short Interest ↑Gap UpTELOTelomir PharmaceuticalsN/A$4.77-7.9%N/AN/A$141.24MN/A0.001Short Interest ↑Gap DownALGSAligos Therapeutics4.149 of 5 stars$39.15-1.7%$75.00+91.6%+135.1%$140.47M$6.00M-2.9490Short Interest ↑High Trading VolumePBYIPuma Biotechnology3.8059 of 5 stars$2.81+2.2%$7.00+149.1%-29.4%$137.94M$243.57M5.85185Analyst RevisionNews Coverage Related Companies and Tools Related Companies ZURA Competitors ELUT Competitors ADAP Competitors FTLF Competitors BMEA Competitors IFRX Competitors NBTX Competitors TELO Competitors ALGS Competitors PBYI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LEXX) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
